Tyra Biosciences, Inc.
TYRA
$36.22
$0.220.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.13% | 26.54% | 29.05% | 34.52% | 52.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.77% | 15.17% | 33.66% | 42.68% | 16.03% |
| Operating Income | -22.77% | -15.17% | -33.66% | -42.68% | -16.03% |
| Income Before Tax | -32.31% | -24.37% | -50.24% | -54.72% | -12.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.31% | -24.37% | -50.24% | -54.72% | -12.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.31% | -24.37% | -50.24% | -54.72% | -12.01% |
| EBIT | -22.77% | -15.17% | -33.66% | -42.68% | -16.03% |
| EBITDA | -22.92% | -15.23% | -33.78% | -42.82% | -15.93% |
| EPS Basic | -30.60% | -22.70% | -47.99% | -36.20% | 18.52% |
| Normalized Basic EPS | -30.60% | -22.71% | -48.04% | -36.20% | 18.52% |
| EPS Diluted | -30.60% | -22.70% | -47.99% | -36.20% | 18.52% |
| Normalized Diluted EPS | -30.60% | -22.71% | -48.04% | -36.20% | 18.52% |
| Average Basic Shares Outstanding | 1.31% | 1.35% | 1.50% | 13.61% | 37.46% |
| Average Diluted Shares Outstanding | 1.31% | 1.35% | 1.50% | 13.61% | 37.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |